Abstract: Breast cancer is a classic hormone-dependent tumor, so endocrine therapy is a major treatment for hormonereceptor -positive [HR (+ )], human-epidermal-growth-factor-2-negative [HER-2 (- )] and advanced breast cancer. Traditional endocrine drugs, such as tamoxifen, aromatase inhibitors (AI) and fulvestrant, have been widely used in advanced (locally advanced or metastatic) postmenopausal patients. However, for this subtype of breast cancer patients, after the appearance of targeted drug, such as mammalian target of rapamycin (mTOR) inhibitors and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, the choice of endocrine therapy has been expanded. There has been various combination of targeted drugs and endocrine therapy. This article aims to explore the application of mTOR inhibitor everolimus combined with fulvestrant in the treatment of AI-resistant estrogen-receptor-positive［ER (+)］/ HER-2 (-) advanced breast cancer.

Key words: breast neoplasms, Fulvestrant, Everolimus, receptors, estrogen